Ocugen, Inc.
Ocugen, Inc. (NASDAQ: OCGN) is a late-stage biotechnology company focused on developing novel gene therapies and regenerative medicine treatments for serious eye diseases and other conditions. The company's website is www.ocugen.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Ocugen, Inc. does
In the company’s own words
Ocugen, Inc. (NASDAQ: OCGN) is a late-stage biotechnology company focused on developing novel gene therapies and regenerative medicine treatments for serious eye diseases and other conditions. The company's website is www.ocugen.com.
The company's primary focus is its modifier gene therapy platform, which represents a paradigm shift from traditional gene therapy approaches. Rather than targeting individual gene mutations, Ocugen's platform utilizes nuclear hormone receptors to address multiple genetic and multifactorial retinal diseases with single therapeutic candidates. OCU400, the company's lead program, is in Phase 3 clinical development for retinitis pigmentosa and has demonstrated durable, clinically meaningful visual acuity improvements across multiple genetic mutations in earlier trials. OCU410 and OCU410ST, also based on the modifier gene therapy platform, are in development for geographic atrophy secondary to dry age-related macular degeneration and Stargardt disease, respectively. OCU410ST recently initiated a Phase 2/3 pivotal trial with anticipated enrollment completion in early 2026.
Beyond its core gene therapy programs, Ocugen maintains a diversified pipeline including OCU200, a novel biologic fusion protein in Phase 1 development for diabetic macular edema and diabetic retinopathy, and NeoCart, an autologous cartilage tissue-engineered implant for knee cartilage repair that has been transferred to a wholly-owned subsidiary. The company also develops an inhaled mucosal vaccine platform including OCU500 for COVID-19, with clinical trials anticipated to begin in 2026 through a partnership with the National Institute of Allergy and Infectious Diseases.
Ocugen operates through strategic partnerships with leading institutions including Harvard Medical School's Schepens Eye Research Institute, Washington University in St. Louis, and the University of Colorado. The company has established manufacturing capabilities through partnerships with CanSino Biologics and operates a renovated GMP facility to support clinical development and commercial manufacturing. The company's intellectual property portfolio includes 80 patents and 66 pending applications covering composition of matter, pharmaceutical compositions, and methods of use for its product candidates.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- MALVERN, PA
- Fiscal year end
- December
- CIK
- 1372299
- SIC
- 2836
Financial performance, year by year
Fiscal 2015–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Ocugen, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Ocugen, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Ocugen, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Ocugen, Inc.’s debt, $2.27M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 6.75%, maturing 2034 to 2034.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Ocugen, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Ocugen, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Ocugen, Inc.'s last four quarterly filings that the numbers alone won't show?”